Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 701–800 of 913
Insights into PINK1/Parkin function and dysfunction from Drosophila models
Park, S., Kozhushko, N., Wight, T. H., & Whitworth, A. J. (2025) · Biochemical Journal · doi:10.1042/bcj20253459 · Cited by 6
Deng, I. B., Garg, S., Zhou, X., & Bobrovskaya, L. (2022) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1402013 · Cited by 6
The Role of Structural Variants in the Genetic Architecture of Parkinson’s Disease
Miano‐Burkhardt, A., Jerez, P. Á., Daida, K., Bandrés‐Ciga, S., & Billingsley, K. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094801 · Cited by 4
“PRKN SV patient fibroblasts [57,58] and mouse models [59–61] have been used to exhibit PRKN loss-of-function effects such as mitochondrial dysfunction and oxidative stress.”
MethodParkin Expression Profile in Dopamine D3 Receptor Knock-Out Mice Brains
D’Agata, V., Tiralongo, A., Castorina, A., Leggio, G. M., Micale, V., Carnazza, M. L., & Drago, F. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9781-y · Cited by 4
“All the experiments were carried out on homozygous DRD3 KO and their WT littermates (male, 8–12 weeks old), obtained from breeding and mating C57BL/6 [20].”
MethodLin, W., & Kang, U. J. (2005) · Journal of Clinical Neurology · doi:10.3988/jcn.2005.1.2.107 · Cited by 4
“tion, increased protein and lipid peroxidation, as well as nigrostriatal functional abnormalities, but without significant loss of dopaminergic neurons.(44,45)”
BackgroundPINK1: One Protein, Multiple Neuroprotective Functions
Valente, E. M., Michiorri, S., Arena, G., & Gelmetti, V. (2009) · Future Neurology · doi:10.2217/fnl.09.39 · Cited by 4
Animal models of Parkinson’s disease and related disorders
Petzinger, G. M., & Jakowec, M. W. (2013) · CRC Press eBooks · doi:10.1201/b14361-17 · Cited by 4
Paraquat-induced Neurodegeneration: a Model of Parkinson's Disease Risk Factors
Monte, D. A. D. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00015-4 · Cited by 4
Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson’s Disease
Du, Y., & Graves, S. M. (2019) · Frontiers in Neural Circuits · doi:10.3389/fncir.2019.00017 · Cited by 5
“Similarly, Parkin deficient animals have no SNc cell loss even at 24 months of age (Goldberg et al., 2003) although animals expressing the Parkin-Q311X mutation show SNc DA neuron loss (40%) at 16 months of age (Lu et al.”
BackgroundProtective Role of Heat Shock Proteins During Neurodegeneration in Parkinson’s Disease
Ghit, A. (2020) · Heat shock proteins · doi:10.1007/7515_2020_23 · Cited by 4
Dysfunction in parkin aggravates inflammatory bone erosion by reinforcing osteoclast activity
Kim, E. Y., Kim, J.-E., Kim, Y.-E., Choi, B., Sohn, D. H., Park, S.-O., Chung, Y., Kim, Y., Robinson, W. H., Kim, Y., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00973-0 · Cited by 5
“Mice of the heterozygous generation were then crossed to generate littermates of the six common genotypes by genotyping, as reported elsewhere [61].”
MethodMitochondrial Dynamics and Autophagy
Stiles, L., Ferree, A. W., & Shirihai, O. S. (2011) · Springer eBooks · doi:10.1007/978-94-007-1291-1_3 · Cited by 4
“These single gene knockout mice display similar functional defects in the dopaminergic system, yet the morphology and numbers of DA neurons are normal (Goldberg et al. 2003; Kitada et al. 2007).”
BackgroundParkinson's Disease: Is It a Toxic Syndrome?
El-Hak, S. G., Ghanem, A. A., Abdel-Ghaffar, H., Dakroury, S. E., & Salama, M. (2010) · Neurology Research International · doi:10.1155/2010/103094 · Cited by 5
Chapter 8 α-Synuclein and Synucleinopathies
Schlossmacher, M. G. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70059-0 · Cited by 10
Identification and characterization of a novel endogenous murine parkin mutation
Ramsey, C. P., & Giasson, B. I. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06605.x · Cited by 5
Mitochondrial dysfunction in Parkinson’s disease: a possible target for neuroprotection
Gleave, J. A., Perri, P. D., & Nash, J. E. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1337-8 · Cited by 5
“In other studies, it was found that the levels of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were similar in the striatum of parkin-de fi cient mice and wild-type mice (Goldberg et al., 2003).”
InfluentialUbiquitin-Dependent Protein Degradation
Hegde, A. N. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00697-3 · Cited by 6
The Ubiquitin–Proteasome System in Parkinson's Disease
McNaught, K. S. P. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch8 · Cited by 4
Tomagra, G., Battaglia, A., Franchino, C., Bonzano, S., Picollo, F., Chiantia, G., de Iure, A., Calabresi, P., Picconi, B., Carbone, E., et al. (2026) · The Journal of Physiology · doi:10.1113/jp288914 · Cited by 3
Dong, N., Xie, Z., Wei, A., Yang, Y., Deng, Y., Cheng, X., Wang, B., Chen, Y., Gu, Y., Yao, J., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02037-x · Cited by 4
The pathological role of Pael-receptor/GPR37 in AR-JP
Takahahshi, R. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.05.013 · Cited by 4
“Regarding the substrates of Parkin, the levels of CDC-rel1, a-synuclein, and synphilin-1 were unchanged [23].”
BackgroundPhysiological and Behavioral Assessment of Tremor in Rodents
Salamone, J. D., Podurgiel, S. J., Collins‐Praino, L. E., & Correa, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00038-x · Cited by 3
EXPERIMENTAL ANIMAL MODELS OF PARKINSON’S DISEASE: AN OVERVIEW
Imran, M., Mishra, A., Usmani, A., & Eqbal, A. (2020) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i11.39131 · Cited by 3
Reim, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.02507-4 · Cited by 3
Gene therapy for Parkinson’s Disease and Ethical Challenges: A Systematic Review
Zohoncon, T. M., Sawadogo, J., Zouré, A. A., Ouattara, A. K., Ouedraogo, M. N. L., Zongo, L., Ouédraogo, P., Djigma, F. W., Nadembega, C., Kaboré, R., et al. (2023) · Advances in Parkinson s Disease · doi:10.4236/apd.2023.122002 · Cited by 3
Depletion of ATP13A2 in adult brain induces a Parkinsonian phenotype in mice and non-human primates
Baekelandt, V. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00814-y · Cited by 3
Inhibition of GABARAP or GABARAPL1 prevents aminoglycoside- induced hearing loss
Li, J., Oh, S. I., Liu, C., & Zhao, B. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416453122 · Cited by 6
“Additionally, some familial forms of Parkinson's disease have been linked to loss - of - function mutations in PINK1 or PRKN in humans, and genetic knockout of Pink1 or Prkn expression in mice results in central nervous system defects ( 49 – 51 ).”
Aerts, L., & Morais, V. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00002-x · Cited by 3
PINK1 (PARK6) and Parkinson's Disease
Valente, E. M., & Ferraris, A. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00005-2 · Cited by 4
Genetic aspects of Parkinson's disease
Mizuno, Y., Hattori, N., & Mochizuki, H. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83009-0 · Cited by 3
“Parkin-deficient mice produced by Goldberg et al. (2003) exhibited nigrostriatal dysfunction without loss of dopaminergic neurons.”
Neuroprotection for Parkinson's Disease
Bézard, E. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00006-3 · Cited by 3
King, L., & Plun‐Favreau, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00005-5 · Cited by 7
Neurodegeneration caused by ER stress?
Takahashi, R. (2004) · Folia Pharmacologica Japonica · doi:10.1254/fpj.124.375 · Cited by 3
RING Fingers and Relatives: Determinators of Protein Fate
Lorick, K. L., Tsai, Y. C., Yang, Y., & Weissman, A. M. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch4 · Cited by 3
Cognitive Disorders: Impairment, Aging, and Dementia
van Goethem, N. P., Lardenoije, R., Kompotis, K., Rutten, B. P. F., Prickaerts, J., & Steinbusch, H. W. M. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679348.ch16 · Cited by 4
RNA Interference Technologies for Understanding and Treating Neurodegenerative Diseases
Lu, B. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:6:1:001 · Cited by 3
“Parkin null mutants have also been created in mouse and NeuroMolecular Medicine Volume 6, 2004 Drosophila (Goldberg et al., 2003; Greene et al., 2003; Itier et al., 2003).”
BackgroundGenetics of Parkinson's Disease
Sinha, K. (2005) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10587_5 · Cited by 3
Rondeau, V., Kalogeraki, M., Roland, L., Nader, Z. A., Gourhand, V., Bonaud, A., Lemos, J. P., Khamyath, M., Moulin, C., Schell, B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.31.542899 · Cited by 3
“TMRE is thought to accumulate specifically in 372 active mitochondria and to decrease in damaged mitochondria which are characterized by a loss 373 of membrane potential (19, 52).”
BackgroundNon‐human primate models of Parkinson's disease: Decoding pathogenesis and advancing therapies
Zhang, S., Yuan, L., Wu, Z., Du, X., Kubiak, J. Z., Yue, F., Yan, X., Jiang, G., & Huang, Y. (2025) · Brain‐X · doi:10.1002/brx2.70032 · Cited by 4
“…although Parkin-null mice exhibited nigrostriatal deficits, no losses of dopaminergic neurons or impairment of the nigrostriatal dopaminergic system were observed, nor the aggregation of α-synuclein, [111,112] indicating that Parkin mutant animal models do not fully replicate the pathology of PD.”
Estrella, L. D., Xu, X., White, C., Manganaro, J. E., Sheldon, L., Farmer, T., & Stauch, K. L. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107084 · Cited by 3
“The hTau (Andorfer et al., 2003; Polydoro et al., 2009), PKO (Goldberg et al., 2003), and Parkin W402A (Kim et al., 2022; Lichter et al., 2023) mice have been described previously.”
Dopamine neurotransmission in Parkinson's disease
Cramb, K. M. L., Noor, H., Wade‐Martins, R., & Cragg, S. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00012-9 · Cited by 2
Herborg, F., Konrad, L., Jørgensen, S. H., Lilja, J. H., Delignat‐Lavaud, B., Posselt, L. P., Pugh, C. F., Bach, S. A., Ratner, C., Awadallah, N., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci169297 · Cited by 3
Modèles animaux des syndromes parkinsoniens
Ghorayeb, I., Bézard, E., Fernagut, P., Bioulac, B. H., & Tison, F. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85154-9 · Cited by 3
Martinez‐Finley, E. J., Chakraborty, S., Caito, S., Fretham, S. J. B., & Aschner, M. (2012) · PubMed · Cited by 4
Wal, A., Wal, P., Vig, H., Samad, A., Khandai, M., & Tyagi, S. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220707101550 · Cited by 3
The PINK1/Parkin pathway of mitophagy exerts a protective effect during prion disease
Ward, A. E., Jessop, F., Faris, R., Hollister, J. R., Shoup, D. W., Race, B., Bosio, C. M., & Priola, S. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298095 · Cited by 3
Yamashita, S.-I., & Kanki, T. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4584-5_16 · Cited by 2
Divino, I. A., da Vieira‐da‐Silva, A. L., Esteca, M. V., Tonon, R. P., da Cruz, F. O. G., Braga, R. R., Ropelle, E. R., Gandra, P. G., & Baptista, I. L. (2025) · Acta Physiologica · doi:10.1111/apha.70082 · Cited by 3
“Parkin knockout mice were generated by Goldberg et al., 2003, and provided by The Jackson Laboratory.”
Blondelle, J., & Lange, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-15263-9_12 · Cited by 2
Fuqua, J. L. (2010) · UKnowledge (University of Kentucky) · Cited by 2
Norazit, A., Mellick, G. D., & Meedeniy, A. C. B. (2012) · InTech eBooks · doi:10.5772/33459 · Cited by 2
“In some of the mouse knockout models, subtle abnormalities of the nigrostriatal pathway or the locus coeruleus noradrenergic system have been observed (Goldberg et al. 2003, von Coelln et al. 2006).”
Rodent Models of Autosomal Recessive Parkinson Disease
Gispert, S., Auburger, G. W. J., Kuruvilla, K. P., & LeDoux, M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00019-6 · Cited by 3
Cognitive Dysfunction in Genetic Mouse Models of Parkinsonism
Fleming, S. M., Jentsch, J. D., & Chesselet, M. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_25 · Cited by 2
Self-citationUbiquitination and Proteasomal Protein Degradation in Neurons
Klimaschewski, L. P. (2007) · Springer eBooks · doi:10.1007/978-0-387-30379-6_22 · Cited by 2
Genetics Of Parkinson’s Disease
Sriram, S. R., Dawson, T. M., & Dawson, V. L. (2005) · Neurological disease and therapy · doi:10.1201/9780849358364.ch24 · Cited by 2
Role of the Innate and Adaptive Immune System in the Pathogenesis of PD
Kannarkat, G. T., & Tansey, M. G. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_3 · Cited by 3
Sasan, H., Hashemabadi, M., Amandadi, M., & Ravan, H. (2020) · Russian Journal of Genetics · doi:10.1134/s1022795420040122 · Cited by 2
Nadia, A., Andleeb, S., Waqar, H., & Rasool, N. (2020) · Global Journal of Biotechnology and Biomaterial Science · doi:10.17352/gjbbs.000013 · Cited by 2
“Previous studies demonstrate that selective mutations in the Parkin have been reported in sporadic Parkinson’s disease [16-18].”
ResultMuqit, M. M. K., & Alessi, D. R. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900021 · Cited by 2
“In many cases, mimicking of human disease mutation in mice yields little or no neurodegenerative phenotype, as demonstrated by the parkin and PINK1 knockout models (Goldberg et al, 2003; Kitada et al, 2007).”
BackgroundThe role of the E3 ubiquitin ligase FBXO7-SCF in early-onset Parkinson's disease
Brockelt, D. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5833 · Cited by 2
Characterization of FBXO7 (PARK15) knockout mice modeling Parkinsonian-Pyramidal Syndrome
Vingill, S. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6254 · Cited by 1
Hess, E. J., & Jinnah, H. A. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50022-0 · Cited by 3
Zhu, M. J., Cortese, G. P., & Waites, C. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/373597 · Cited by 2
“However, other groups report that Parkin mutation/loss-of-function decreases neuronal excitability and/or AMPAR EPSCs, as well as AMPAR levels in brain tissue from knockout mice and human patients (15, 16, 19, 26, 54, 55).”
BackgroundExocytosis, Mitochondrial Injury and Oxidative Stress in Neurodegenerative Diseases
Zanin, M., & Keating, D. J. (2009) · Contemporary clinical neuroscience · doi:10.1007/978-1-60327-342-8_4 · Cited by 2
“PD mouse models exhibit various alterations in dopaminergic neuronal function prior to the degeneration of dopaminergic brain areas [55, 58, 59 ].”
BackgroundSong, P., & Krainc, D. (2024) · Protein & Cell · doi:10.1093/procel/pwae064 · Cited by 1
“…(autosomal recessive, juvenile) 2, (PARK2) are known to cause early-onset PD (Kitada et al., 1998), mouse models of these mutations have not successfully replicated the key pathological features of the disease, such as neuro-degeneration and pS129-α -syn accumulation (Goldberg et al., 2003).”
Role of mitophagy and mitochondria in aging and cellular senescence
Liang, X. F., Poulton, J., & Lechuga‐Vieco, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15260-3.00006-5 · Cited by 1
Interactions of VMAT2 with CDCrel-1 and Parkin in Methamphetamine Neurotoxicity
Chauhan, H., Carruthers, N. J., Stemmer, P. M., Schneider, B. L., & Moszczyńska, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313070 · Cited by 3
Spector, E., Michaeli, L., Nitzan, A., Grobe, H., Axel, G., Abu‐Shach, U. B., Zinger, H., Carvalho, C. A., Zaidel‐Bar, R., & Broday, L. (2025) · The FASEB Journal · doi:10.1096/fj.202402785rrr · Cited by 1
“Most genetic model systems that have been studied to understand the contribution of Parkin to PD used deletion alleles [14, 18, 20, 65, 66].”
Volovsky, M., Rodríguez‐Eguren, A., Ergun, Y., Yildirim, R. M., Şahin, G. N., García-Milian, R., Mehta, S. S., Turanli, L., Cervelló, I., Scott, R., et al. (2026) · npj Aging · doi:10.1038/s41514-026-00332-6 · Cited by 2
“This approach is consistent with the generation and characterization of Parkin KO mice as described by Goldberg and colleagues 43 .”
Animal Models of Parkinson’s Disease Induced by Toxins and Genetic Manipulation
Hisahara, S., & Shimoham, S. (2012) · InTech eBooks · doi:10.5772/19860 · Cited by 1
Parkinson’s Disease: Insights from the Laboratory and Clinical Therapeutics
Zhou, J.-Y., Yu, Y., Zhu, X.-L., Ng, C.-P., Lü, G., & Poo, W.-S. (2012) · InTech eBooks · doi:10.5772/33092 · Cited by 1
Overview: rodent and fish models of parkinson's disease
Dauer, W. T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00016-6 · Cited by 1
Kuenstling, M. V., Szlachetka, A. M., & Mosley, R. L. (2013) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4614-8794-4_34 · Cited by 1
Magen, I., & Chesselet, M. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.031 · Cited by 2
Self-citationMitochondria, the Synapse, and Neurodegeneration
Chrysostomou, A., & Turnbull, D. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-28637-2_9 · Cited by 3
Fleming, S. M., & Schallert, T. J. (2011) · Neuromethods · doi:10.1007/978-1-61779-298-4_17 · Cited by 1
Self-citationPietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1
Mitochondrial Therapeutic Approaches in Parkinson’s Disease
Esteves, A. R., Silva, D. F., G-Fernandes, M., Gomes, R., & Cardoso, S. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-42139-1_9 · Cited by 1
Modeling Disorders of Movement
LeDoux, M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00002-0 · Cited by 1
Gock, N., Follett, J., Rintoul, G. L., Beischlag, T. V., & Lee, F. J. S. (2022) · Synapse · doi:10.1002/syn.22224 · Cited by 3
Bonifati, V. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.007 · Cited by 2
Nakai, A., Fukushima, Y., Yamamoto, A., Amatsu, Y., Chen, X., Nishigori, M., Yoshioka, Y., Kaneko, M., Koshiba, T., & Watanabe, T. (2024) · FEBS Letters · doi:10.1002/1873-3468.14876 · Cited by 2
“Surprisingly, however, mice deficient in Park2 alone do not develop strong motor dysfunction phenotypes, nor do they display accelerated dopaminergic neuron loss [34 – 37].”
Parkin R274W mutation affects muscle and mitochondrial physiology
Sevegnani, M., Lama, A., Girardi, F., Hess, M. W., Rueda, M. P. C., Pichler, I., Biressi, S., & Piccoli, G. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167302 · Cited by 1
The Role of Alpha-Synuclein Pathology
Fu, Y., Tanglay, O., Li, H., & Halliday, G. M. (2024) · Neuromethods · doi:10.1007/978-1-0716-4083-8_2 · Cited by 2
Calpain Proteolysis and the Etiology of Parkinson’s Disease: An Emerging Hypothesis
Crocker, S. J., Smith, P. D., & Park, D. S. (2006) · Springer eBooks · doi:10.1007/0-387-23101-3_2 · Cited by 1
Parkin and Parkinson’s Disease
Tay, S.-P., Grace, G. Y., Calvin, W. S., & Lim, K. (2011) · InTech eBooks · doi:10.5772/16990 · Cited by 2
“…from these mice revealed deficits in dopamine handling, reduced mitochondrial respiration and antioxidant capacity, as well as increased ROS-mediated damage, all of which are consistent with the implicated cellular roles of parkin (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004).”
Clinical Disease Progression in Parkinson’s Disease
Alves, G. W. (2006) · NVA (Nasjonalt vitenarkiv) · Cited by 2
Dysmyelination with preservation of transverse bands in a long‐lived allele of the quaking mouse
Chaverneff, F., Mierzwa, A. J., Weinstock, M. S., Ketcham, M., Lang, E. J., & Rosenbluth, J. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23670 · Cited by 1
Parkin modulates gene expression in control and ceramide-treated PC12 cells
Unschuld, P. G., Dächsel, J. C., Darios, F. D., Kohlmann, A., Casademunt, E., Lehmann‐Horn, K., Dichgans, M., Ruberg, M., Brice, A., Gasser, T., et al. (2006) · Aktuelle Neurologie · doi:10.1055/s-2006-953145 · Cited by 1
Genetic Models of Familial Parkinson's Disease
Ying, M., Dawson, V. L., & Dawson, T. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00017-8 · Cited by 1
Drosophila as a Neurotoxicological Model
Lawal, H. O., & Krantz, D. E. (2018) · Methods in pharmacology and toxicology · doi:10.1007/7653_2018_12 · Cited by 1
Verma, M., Basu, S., Singh, M., Rachana, R., Kaur, S., & Goel, N. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch008 · Cited by 1
Aging and Parkinson’s Disease: Pathological Insight on Model Mice
Sato, S., & Hattori, N. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_23 · Cited by 1
Ubiquitin and Protein Degradation in Synapse Function
Helton, T. D., & Ehlers, M. (2008) · Springer eBooks · doi:10.1007/978-0-387-77232-5_19 · Cited by 1
“Consistent with a role in synaptic transmission, parkin null mice show subtle behavioral deficits and altered excitability in the hippocampus and striatum (96, 126, 286).”
BackgroundNOVEL CDNF/MANF PROTEIN FAMILY: MOLECULAR STRUCTURE, EXPRESSION AND NEUROTROPHIC ACTIVITY
Lindholm, P. (2009) · Helda - University of Helsinki Institutional Repository · Cited by 1
Neurofilament light as a marker for neurodegenerative diseases
Norgren, N. (2004) · DiVA at Umeå University (Umeå University) · Cited by 2
Protein‐handling dysfunction in Parkinson's disease
McNaught, K. S. P. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83028-4 · Cited by 4
Tetrahydroisoquinoline Neurotoxins in Parkinson Disease
DeCuypere, M. G. (2010) · doi:10.21007/etd.cghs.2010.0067 · Cited by 2
“The finding that Parkin KO mice have a normal level of α-synuclein 13 raised the possibility that it is not a normal substrate for Parkin and that other degradation systems are involved (Goldberg et al 2003).”
BackgroundEnvironmental Explorations of Parkinson's Disease Using Rodent Genetic Models
Chesselet, M., & Fernagut, P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00021-x · Cited by 1
Self-citationGenetic Models of Parkinson’s Disease
Palubinsky, A. M., Lizama, B. N., Miller, D. L., & McLaughlin, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00014-5 · Cited by 1
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.